These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 17324829)

  • 1. Topical pimecrolimus in the treatment of vitiligo.
    Boone B; Ongenae K; Van Geel N; Vernijns S; De Keyser S; Naeyaert JM
    Eur J Dermatol; 2007; 17(1):55-61. PubMed ID: 17324829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repigmentation of pretibial vitiligo with calcineurin inhibitors under occlusion.
    Hartmann A; Bröcker EB; Hamm H
    J Dtsch Dermatol Ges; 2008 May; 6(5):383-5. PubMed ID: 18042249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo.
    Stinco G; Piccirillo F; Forcione M; Valent F; Patrone P
    Eur J Dermatol; 2009; 19(6):588-93. PubMed ID: 19651562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial.
    Radakovic S; Breier-Maly J; Konschitzky R; Kittler H; Sator P; Hoenigsmann H; Tanew A
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):951-3. PubMed ID: 19496898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo.
    Lo YH; Cheng GS; Huang CC; Chang WY; Wu CS
    J Dermatol; 2010 Feb; 37(2):125-9. PubMed ID: 20175845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo.
    Coskun B; Saral Y; Turgut D
    Eur J Dermatol; 2005; 15(2):88-91. PubMed ID: 15757818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo.
    Passeron T; Ostovari N; Zakaria W; Fontas E; Larrouy JC; Lacour JP; Ortonne JP
    Arch Dermatol; 2004 Sep; 140(9):1065-9. PubMed ID: 15381545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study.
    Dawid M; Veensalu M; Grassberger M; Wolff K
    J Dtsch Dermatol Ges; 2006 Nov; 4(11):942-6. PubMed ID: 17081269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo.
    Xu AE; Zhang DM; Wei XD; Huang B; Lu LJ
    Int J Dermatol; 2009 Jan; 48(1):86-90. PubMed ID: 19126059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical pimecrolimus: a new horizon for vitiligo treatment?
    Sendur N; Karaman G; Saniç N; Savk E
    J Dermatolog Treat; 2006; 17(6):338-42. PubMed ID: 17853306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: a randomized placebo-controlled study.
    Farajzadeh S; Daraei Z; Esfandiarpour I; Hosseini SH
    Pediatr Dermatol; 2009; 26(3):286-91. PubMed ID: 19706089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus.
    Lubaki LJ; Ghanem G; Vereecken P; Fouty E; Benammar L; Vadoud-Seyedi J; Dell'Anna ML; Briganti S; Picardo M; Heenen M
    Arch Dermatol Res; 2010 Mar; 302(2):131-7. PubMed ID: 19547993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial.
    Esfandiarpour I; Ekhlasi A; Farajzadeh S; Shamsadini S
    J Dermatolog Treat; 2009; 20(1):14-8. PubMed ID: 18608735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pimecrolimus cream in repigmentation of vitiligo.
    Seirafi H; Farnaghi F; Firooz A; Vasheghani-Farahani A; Alirezaie NS; Dowlati Y
    Dermatology; 2007; 214(3):253-9. PubMed ID: 17377388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical immunomodulators are effective for treatment of vitiligo.
    Choi CW; Chang SE; Bak H; Choi JH; Park HS; Huh CH; Kim CW; Kim SE; Mun SK; Kim BJ; Kim MN
    J Dermatol; 2008 Aug; 35(8):503-7. PubMed ID: 18789070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo.
    Köse O; Arca E; Kurumlu Z
    J Dermatolog Treat; 2010 May; 21(3):133-9. PubMed ID: 20394489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-month prospective study.
    Hartmann A; Bröcker EB; Hamm H
    Acta Derm Venereol; 2008; 88(5):474-9. PubMed ID: 18779885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis.
    Prescrire Int; 2004 Dec; 13(74):209-12. PubMed ID: 15599989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo.
    Lepe V; Moncada B; Castanedo-Cazares JP; Torres-Alvarez MB; Ortiz CA; Torres-Rubalcava AB
    Arch Dermatol; 2003 May; 139(5):581-5. PubMed ID: 12756094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases.
    Silverberg NB; Lin P; Travis L; Farley-Li J; Mancini AJ; Wagner AM; Chamlin SL; Paller AS
    J Am Acad Dermatol; 2004 Nov; 51(5):760-6. PubMed ID: 15523355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.